← All trials
NCT05010772
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2021
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Aug 18, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 125
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.